HSIC
Henry Schein, Inc.
NASDAQ · Healthcare · Medical - Distribution · US
$89.81
−1.16%Year over year
Reported trailing growth
- Revenue
- +6.5%
- EBITDA
- +7.3%
- EBIT
- +0.0%
- EPS
- +10.2%
- Free cash flow
- +50.6%
- Operating cash flow
- +36.7%
Forward estimates
Based on analyst estimates
- Revenue
- +3.7%
- EBITDA
- +31.6%
- EPS
- +64.1%
Three-year CAGR
- Revenue
- +1.4%
- EBITDA
- +1.0%
- EBIT
- -6.9%
- Net income
- -9.6%
- EPS
- -5.9%
- Free cash flow
- +4.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026